Providers available through a vendor are subject to the vendor’s credentialing process and requirements, not MetLife’s.
#LIFE FINAL PRINT COVER UPDATE#
This update to the Commission presents advances and discusses persisting and new challenges in prevention, clinical care, and research into TBI.1 Savings from enrolling in a MetLife vision benefits plan will depend on various factors including, the cost of the plan, how often participants visit an eye-care professional and the cost of services and eyewear received.Ģ Certain providers may participate with MetLife through an agreement that MetLife has with a vendor. However, many of these advances have yet to achieve routine clinical implementation, and major issues persist, particularly in the care of patients with TBI in low-income and middle-income countries. There has clearly been substantial progress in the past 5 years. Of all common neurological disorders, traumatic brain injury (TBI) has the highest incidence and poses a substantial challenge to public health. TBI is increasingly being recognised as a chronic disease with long-term consequences, such as an increased risk of late-onset neurodegeneration. The first Lancet Neurology Commission on TBI, published in 2017, provided expert recommendations to reduce the global burden of TBI, calling for concerted action. The Commission provided the foundation for subsequent research, informed strategies of major funding organisation, and has been used to brief legislators and inform policy. Implementing these solutions will ensure future outbreak research and actionable outcomes will be robust, accurate, and equitable. The solutions include standardising data capture and codes, mandating adherence to reporting guidelines developed for modelling studies, ensuring datasets are representative across a range of sociodemographic factors, and encouraging better communication of findings to the public via a sustainable information-sharing system.
#LIFE FINAL PRINT COVER SERIES#
This Series in The Lancet Digital Health explores these challenges and identifies potential solutions that can be applied to future infectious disease outbreaks. But these efforts have been hampered by challenges to collecting and sharing real-world data and developing accurate forecasting models. Treatments are emerging for optic neuropathies, including immunotherapies and genetic therapies.ĭuring the global COVID-19 pandemic, researchers and clinicians have investigated how best to leverage technology and big data to provide virtual clinical care, model the effect of health policies on transmission, identify novel therapeutic treatments, and more. Also reviewed in the Series, a unifying feature in the pathophysiology of hereditary disorders of the optic nerve is mitochondrial dysfunction. Early clinical recognition of optic neuritis is, therefore, important for prognosis and treatment. Also reviewed in this Series, new evidence shows that optic neuritis can frequently indicate autoimmune neurological disorders, including multiple sclerosis and the recently recognised disease categories of aquaporin-4 antibody-associated neuromyelitis optica spectrum disorder and myelin-oligodendrocyte glycoprotein antibody-associated disease. Multimodality optic nerve imaging-including fundus photography, optical coherence tomography, and MRI-has greatly advanced the diagnosis and follow-up of patients with optic neuropathies. This Series provides an update on the clinical, imaging, and laboratory findings that differentiate these disorders, allowing clinicians to focus their diagnostic studies and optimise treatments. Optic neuropathies can reflect a wide range of pathophysiologies, both acquired and inherited. The Lancet Regional Health – Western Pacific.The Lancet Regional Health – Southeast Asia.The Lancet Gastroenterology & Hepatology.
0 kommentar(er)
